XSpray Pharma AB (XSPRAY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has a cash flow conversion efficiency ratio of -0.054x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-30.68 Million ≈ $-3.30 Million USD) by net assets (Skr569.36 Million ≈ $61.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XSpray Pharma AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
XSpray Pharma AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how XSpray Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
XSpray Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XSpray Pharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Se Gyung Hi Tech Co.Ltd
KQ:148150
|
0.004x |
|
Adhi Karya Persero Tbk
JK:ADHI
|
0.006x |
|
Deutsch Motors Inc
KQ:067990
|
0.046x |
|
Champions Oncology Inc
NASDAQ:CSBR
|
-0.306x |
|
seha corporation
KO:027970
|
0.076x |
|
Houston American Energy Corporation
NYSE MKT:HUSA
|
-0.108x |
|
Kalleback Property Invest AB
ST:KAPIAB
|
0.049x |
|
Jiin Ming Industry Co Ltd
TWO:3230
|
0.026x |
Annual Cash Flow Conversion Efficiency for XSpray Pharma AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of XSpray Pharma AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see XSPRAY company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr604.65 Million ≈ $65.07 Million |
Skr-193.16 Million ≈ $-20.79 Million |
-0.319x | +10.48% |
| 2024-12-31 | Skr623.10 Million ≈ $67.06 Million |
Skr-222.37 Million ≈ $-23.93 Million |
-0.357x | -21.74% |
| 2023-12-31 | Skr693.41 Million ≈ $74.62 Million |
Skr-203.28 Million ≈ $-21.88 Million |
-0.293x | -47.94% |
| 2022-12-31 | Skr556.02 Million ≈ $59.84 Million |
Skr-110.18 Million ≈ $-11.86 Million |
-0.198x | -127.22% |
| 2021-12-31 | Skr591.75 Million ≈ $63.68 Million |
Skr-51.61 Million ≈ $-5.55 Million |
-0.087x | -6.31% |
| 2020-12-31 | Skr582.59 Million ≈ $62.70 Million |
Skr-47.79 Million ≈ $-5.14 Million |
-0.082x | +10.46% |
| 2019-12-31 | Skr373.71 Million ≈ $40.22 Million |
Skr-34.24 Million ≈ $-3.68 Million |
-0.092x | -55.76% |
| 2018-12-31 | Skr301.72 Million ≈ $32.47 Million |
Skr-17.75 Million ≈ $-1.91 Million |
-0.059x | +17.07% |
| 2017-12-31 | Skr155.66 Million ≈ $16.75 Million |
Skr-11.04 Million ≈ $-1.19 Million |
-0.071x | -89.00% |
| 2016-12-31 | Skr46.47 Million ≈ $5.00 Million |
Skr-1.74 Million ≈ $-187.68K |
-0.038x | +96.45% |
| 2015-12-31 | Skr12.26 Million ≈ $1.32 Million |
Skr-12.96 Million ≈ $-1.40 Million |
-1.057x | -- |
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more